Compare iShares Core Growth Allocation ETF (AOR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Sanofi SA — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| AOR | SNY | |
|---|---|---|
52-Week High | $70.12 | $52.34 |
52-Week Low | $62.26 | $41.33 |
Market Cap | — | $104.30B |
Sector | — | Health |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $70.11, up 0.27% on the day. Technical indicators show a bullish trend with strong moving average signals, though the RSI suggests potential overbought conditions. The ETF maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low expense ratio of 0.20%.
The outlook for AOR is mixed; it offers diversified exposure and cost efficiency, but has underperformed the S&P 500 over the past decade. Key risks include market volatility and allocation strategy limitations. Analyst sentiment is generally positive for long-term core holdings.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
